In a single-arm trial of 47 patients with advanced HCC undergoing triple therapy with a PD-1 inhibitor, a TKI, and conformal radiation therapy, those with fewer than 2 PD-L1+ CTCs at baseline exhibited superior efficacy, including higher ORR and longer OS [83]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.